<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2680857-A1" country="EP" doc-number="2680857" kind="A1" date="20140108" family-id="49680730" file-reference-id="297131" date-produced="20180823" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146586804" ucid="EP-2680857-A1"><document-id><country>EP</country><doc-number>2680857</doc-number><kind>A1</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-12707503-A" is-representative="NO"><document-id mxw-id="PAPP154848996" load-source="docdb" format="epo"><country>EP</country><doc-number>12707503</doc-number><kind>A</kind><date>20120224</date><lang>EN</lang></document-id><document-id mxw-id="PAPP196210822" load-source="docdb" format="original"><country>EP</country><doc-number>12707503.4</doc-number><date>20120224</date></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140555464" ucid="EP-12707503-A" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>12707503</doc-number><kind>A</kind><date>20120224</date></document-id></priority-claim><priority-claim mxw-id="PPC140547162" ucid="EP-2011053345-W" linkage-type="A" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>2011053345</doc-number><kind>W</kind><date>20110304</date></document-id></priority-claim><priority-claim mxw-id="PPC140550094" ucid="EP-2012053144-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>2012053144</doc-number><kind>W</kind><date>20120224</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1989320037" load-source="docdb">A61P  31/10        20060101ALI20120928BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989323237" load-source="docdb">A61K  31/685       20060101AFI20120928BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL1989652061" load-source="docdb" scheme="CPC">A61K  31/685       20130101 FI20130101BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132365045" lang="DE" load-source="patent-office">OLEYL-PHOSPHOCHOLIN ZUR BEHANDLUNG VON MYKOSE</invention-title><invention-title mxw-id="PT132365046" lang="EN" load-source="patent-office">OLEYL PHOSPHOCHOLINE FOR THE TREATMENT OF MYCOSIS</invention-title><invention-title mxw-id="PT132365047" lang="FR" load-source="patent-office">OLÉYL-PHOSPHOCHOLINE POUR LE TRAITEMENT DES MYCOSES</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR919509336" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>DAFRA PHARMA RES &amp; DEV BVBA</last-name><address><country>BE</country></address></addressbook></applicant><applicant mxw-id="PPAR919514174" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>DAFRA PHARMA RESEARCH &amp; DEVELOPMENT BVBA</last-name></addressbook></applicant><applicant mxw-id="PPAR919010161" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Dafra Pharma Research &amp; Development BVBA</last-name><iid>101060274</iid><address><street>Slachthuisstraat 30/7</street><city>2300 Turnhout</city><country>BE</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919544165" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>JANSEN FRANS HERWIG</last-name><address><country>BE</country></address></addressbook></inventor><inventor mxw-id="PPAR919519617" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>JANSEN, FRANS HERWIG</last-name></addressbook></inventor><inventor mxw-id="PPAR919018451" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>JANSEN, FRANS HERWIG</last-name><address><street>Witte Bremlaan 30</street><city>B-2360 Oud-Turnhout</city><country>BE</country></address></addressbook></inventor><inventor mxw-id="PPAR919509894" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>FORTIN ANNIE MARIE</last-name><address><country>CA</country></address></addressbook></inventor><inventor mxw-id="PPAR919508268" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>FORTIN, Annie Marie</last-name></addressbook></inventor><inventor mxw-id="PPAR919012081" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>FORTIN, Annie Marie</last-name><address><street>6613 29eme Avenue Montreal</street><city>Québec, Québec H1T 3H3</city><country>CA</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR919007553" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>van Kooij, Adriaan</last-name><suffix>et al</suffix><iid>100765192</iid><address><street>Arnold &amp; Siedsma Sweelinckplein 1</street><city>2517 GK Den Haag</city><country>NL</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="EP-2012053144-W"><document-id><country>EP</country><doc-number>2012053144</doc-number><kind>W</kind><date>20120224</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2012119870-A1"><document-id><country>WO</country><doc-number>2012119870</doc-number><kind>A1</kind><date>20120913</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS549764980" load-source="docdb">AL</country><country mxw-id="DS549845662" load-source="docdb">AT</country><country mxw-id="DS549765369" load-source="docdb">BE</country><country mxw-id="DS549916619" load-source="docdb">BG</country><country mxw-id="DS549776468" load-source="docdb">CH</country><country mxw-id="DS549765370" load-source="docdb">CY</country><country mxw-id="DS549845663" load-source="docdb">CZ</country><country mxw-id="DS549764993" load-source="docdb">DE</country><country mxw-id="DS549765371" load-source="docdb">DK</country><country mxw-id="DS549765372" load-source="docdb">EE</country><country mxw-id="DS549859659" load-source="docdb">ES</country><country mxw-id="DS549916620" load-source="docdb">FI</country><country mxw-id="DS549776477" load-source="docdb">FR</country><country mxw-id="DS549764994" load-source="docdb">GB</country><country mxw-id="DS549765377" load-source="docdb">GR</country><country mxw-id="DS549764995" load-source="docdb">HR</country><country mxw-id="DS549845664" load-source="docdb">HU</country><country mxw-id="DS549776478" load-source="docdb">IE</country><country mxw-id="DS549765378" load-source="docdb">IS</country><country mxw-id="DS549916621" load-source="docdb">IT</country><country mxw-id="DS549765379" load-source="docdb">LI</country><country mxw-id="DS549916622" load-source="docdb">LT</country><country mxw-id="DS549844495" load-source="docdb">LU</country><country mxw-id="DS549916623" load-source="docdb">LV</country><country mxw-id="DS549916624" load-source="docdb">MC</country><country mxw-id="DS549844496" load-source="docdb">MK</country><country mxw-id="DS549844497" load-source="docdb">MT</country><country mxw-id="DS549844502" load-source="docdb">NL</country><country mxw-id="DS549845665" load-source="docdb">NO</country><country mxw-id="DS549844503" load-source="docdb">PL</country><country mxw-id="DS549765380" load-source="docdb">PT</country><country mxw-id="DS549846736" load-source="docdb">RO</country><country mxw-id="DS549765385" load-source="docdb">RS</country><country mxw-id="DS549844504" load-source="docdb">SE</country><country mxw-id="DS549764996" load-source="docdb">SI</country><country mxw-id="DS549845670" load-source="docdb">SK</country><country mxw-id="DS549845671" load-source="docdb">SM</country><country mxw-id="DS549859660" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><abstract mxw-id="PA100072127" ref-ucid="WO-2012119870-A1" lang="EN" load-source="patent-office"><p num="0000">The present invention relates to the use of oleyl phosphocholine (C18:1-PC), or OlPC,for the treatment of mycosis, and especially for the treatment of mycosis such as mycosis caused by pathogens belonging to a genus selected from the group consisting of Candida, Aspergillus, Fusarium, Cryptococcus, Microsporum, Sporothrix, Trichophytonand Scedosporium, for example, Candida albicans, Candida parapsilosis, Candida glabrata, Candida krusei, Aspergillus fumigatus, Aspergillus niger, Aspergillus terreus, Fusarium solani, Scedosporium prolifacans, Cryptococcus neoformans, Microsporum canis, Sporothrix schenkii, Trichophyton rubrum, Trichophyton mentagrophytes, Aspergillus fumigatus, Fusarium oxysporum.</p></abstract><abstract mxw-id="PA100340167" ref-ucid="WO-2012119870-A1" lang="EN" source="national office" load-source="docdb"><p>The present invention relates to the use of oleyl phosphocholine (C18:1-PC), or OlPC,for the treatment of mycosis, and especially for the treatment of mycosis such as mycosis caused by pathogens belonging to a genus selected from the group consisting of Candida, Aspergillus, Fusarium, Cryptococcus, Microsporum, Sporothrix, Trichophytonand Scedosporium, for example, Candida albicans, Candida parapsilosis, Candida glabrata, Candida krusei, Aspergillus fumigatus, Aspergillus niger, Aspergillus terreus, Fusarium solani, Scedosporium prolifacans, Cryptococcus neoformans, Microsporum canis, Sporothrix schenkii, Trichophyton rubrum, Trichophyton mentagrophytes, Aspergillus fumigatus, Fusarium oxysporum.</p></abstract><abstract mxw-id="PA100072128" ref-ucid="WO-2012119870-A1" lang="FR" load-source="patent-office"><p num="0000">La présente invention concerne l'utilisation d'oléyl-phosphocholine (C18:1-PC), ou OlPC, pour le traitement d'une mycose, et en particulier le traitement d'une mycose telle qu'une mycose causée par des agents pathogènes appartenant à un genre choisi dans le groupe constitué de <i>Candida</i>,<i> Aspergillus</i>,<i> Fusarium</i>,<i> Cryptococcus</i>,<i> Microsporum</i>,<i> Sporothrix</i>,<i> Trichophytonand Scedosporium</i>, par exemple, <i>Candida albicans</i>,<i> Candida parapsilosis</i>,<i> Candida glabrata</i>,<i> Candida krusei</i>,<i> Aspergillus fumigatus</i>,<i> Aspergillus niger</i>,<i> Aspergillus terreus</i>,<i> Fusarium solani</i>,<i> Scedosporium prolifacans</i>,<i> Cryptococcus neoformans</i>,<i> Microsporum canis</i>,<i> Sporothrix schenkii</i>,<i> Trichophyton rubrum</i>,<i> Trichophyton mentagrophytes</i>,<i> Aspergillus fumigatus</i>,<i> Fusarium oxysporum.</i>
</p></abstract><abstract mxw-id="PA100340168" ref-ucid="WO-2012119870-A1" lang="FR" source="national office" load-source="docdb"><p>La présente invention concerne l'utilisation d'oléyl-phosphocholine (C18:1-PC), ou OlPC, pour le traitement d'une mycose, et en particulier le traitement d'une mycose telle qu'une mycose causée par des agents pathogènes appartenant à un genre choisi dans le groupe constitué de Candida, Aspergillus, Fusarium, Cryptococcus, Microsporum, Sporothrix, Trichophytonand Scedosporium, par exemple, Candida albicans, Candida parapsilosis, Candida glabrata, Candida krusei, Aspergillus fumigatus, Aspergillus niger, Aspergillus terreus, Fusarium solani, Scedosporium prolifacans, Cryptococcus neoformans, Microsporum canis, Sporothrix schenkii, Trichophyton rubrum, Trichophyton mentagrophytes, Aspergillus fumigatus, Fusarium oxysporum.</p></abstract><description mxw-id="PDES51373780" ref-ucid="WO-2012119870-A1" lang="EN" load-source="patent-office"><!-- EPO <DP n="2"/>--><p id="p0001" num="0001"> OLEYL PHOSPHOCHOLINE FOR THE TREATMENT OF MYCOSIS </p><p id="p0002" num="0002">Description The present invention relates to the treatment of mycosis, and especially the treatment of virulent or </p><p id="p0003" num="0003">invasive mycosis such as candidemia, cryptococcosis or aspergillosis. </p><p id="p0004" num="0004"> Mycosis is a fungal infection of vertebrates, including humans. Mycosis is a common infection, and a variety of environmental and physiological conditions can contribute to the development of mycosis. Inhalation of fungal spores or localized colonization of the skin may initiate persistent infections and, accordingly, mycosis often starts in the lungs or on the skin. </p><p id="p0005" num="0005"> Mycosis can be classified according to the tissue initially colonized. </p><p id="p0006" num="0006"> Superficial mycosis is limited to the outermost layers of the skin and hair. An example of superficial mycosis is Tinea versicolor, a fungus infection that </p><p id="p0007" num="0007">commonly affects young people. </p><p id="p0008" num="0008"> Cutaneous mycosis extends deeper into the epidermis and also includes invasive hair and nail diseases. These diseases are restricted to the keratinized layers of the skin, hair, and nails. Unlike the superficial mycosis, host immune responses may be evoked resulting in pathologic changes expressed in the deeper layers of the skin. </p><p id="p0009" num="0009"> Subcutaneous mycosis involves the dermis, subcutaneous tissues, muscle, and fascia. These infections are chronic and can be initiated by piercing trauma </p><p id="p0010" num="0010">functioning as a port of entry for the fungi. These </p><p id="p0011" num="0011">infections are difficult to treat and may require surgical interventions such as debridement. 
<!-- EPO <DP n="3"/>-->
 Systemic mycosis generally starts with infection of the lungs, but also other ports of entry are known, and may spread to many organ systems and tissues. Pathogenic fungi causing systemic mycosis are inherently virulent. </p><p id="p0012" num="0012"> A special class of systemic mycosis is systemic mycosis caused by opportunistic pathogens. Systemic mycosis caused by opportunistic pathogens is often an infection in patients with immune deficiencies. Examples of </p><p id="p0013" num="0013">immunocompromised conditions include AIDS, alteration of normal flora by antibiotics, immunosuppressive therapy and metastatic cancer. Examples of opportunistic mycosis include candidiasis, cryptococcosis and aspergillosis. </p><p id="p0014" num="0014"> Pathogenic fungi and especially pathogenic fungi causing systemic mycosis are, for example, fungi belonging to the genus Candida, the genus Aspergillus and the genus Cryptococcus . </p><p id="p0015" num="0015"> Candida species, such as Candida albicans, are major human pathogens that are known for causing opportunist infections in immunocompromised hosts such as transplant patients, patients suffering from AIDS and cancer patients. Infections are difficult to treat and can be very serious, i.e. 30% to 40% of the systemic infections result in death. </p><p id="p0016" num="0016"> Aerosolized Aspergillus spores are found nearly everywhere and constant exposure to Aspergillus is common. Aspergillus can generally cause serious mycosis in three ways: through the production of mycotoxins; through </p><p id="p0017" num="0017">induction of allergenic responses; and through systemic infections . </p><p id="p0018" num="0018"> The most common pathogenic species are Aspergillus fumigatus and Aspergillus flavus. Aspergillus flavus </p><p id="p0019" num="0019">produces an aflatoxin which is both a toxin and a </p><p id="p0020" num="0020">carcinogen . 
<!-- EPO <DP n="4"/>-->
 Mycosis caused by Aspergillus is generally </p><p id="p0021" num="0021">designated as aspergillosis. The symptoms of aspergillosis include fever, cough, chest pain or breathlessness . </p><p id="p0022" num="0022"> Cryptococcus neoformans can cause a severe form of meningitis and meningo-encephalitis for example in HIV positive patients and AIDS. Cryptococcus neoformans is a major human and animal pathogen. Cryptococcus laurentii and Cryptococcus albidus have been known to cause moderate-to- severe disease in human patients with compromised immunity. Cryptococcus gattii can cause disease in non- immunocompromised people. </p><p id="p0023" num="0023"> Presently, amphotericin B, voriconazole and itraconazole are amongst the most commonly used medicaments to combat severe forms of mycosis such as subcutaneous mycosis and systemic mycosis. However, serious side effects are associated with these drugs. </p><p id="p0024" num="0024"> Amphotericin B is a polyene anti-fungal drug often used intravenously for systemic mycosis. It was originally extracted from Streptomyces nodosus, a filamentous </p><p id="p0025" num="0025">bacterium, in 1955. </p><p id="p0026" num="0026"> Two amphotericins, amphotericin A and amphotericin B are known, but only B is used clinically, because it is significantly more active in vivo. Amphotericin A is almost identical to amphotericin B (having a double C=C bond between the 27th and 28th carbon) , but has little anti<sup>¬</sup> fungal activity has been observed. </p><p id="p0027" num="0027"> Currently, the drug is available as plain amphotericin B, a cholesteryl sulfate complex, a lipid complex, and as a liposomal formulation. </p><p id="p0028" num="0028"> One of the main intravenous uses of amphotericin B is in treating various systemic mycoses, including </p><p id="p0029" num="0029">cryptococcal meningitis, for example in critically ill, comorbidly infected or immunocompromised patients. 
<!-- EPO <DP n="5"/>-->
 Another intravenous use of amphotericin B is as a drug of last resort in otherwise untreatable parasitic protozoan infections such as visceral leishmaniasis and primary amoebic meningoencephalitis. </p><p id="p0030" num="0030"> Amphotericin B is well-known for its severe and potentially lethal side effects. Very often, a serious acute reaction after the infusion (1 to 3 hours later) is noted, consisting of high fever, shaking chills, hypotension, anorexia, nausea, vomiting, headache, dyspnea and tachypnea, drowsiness, and generalised weakness. To decrease the likelihood and severity of the symptoms, initial doses should be low, and increased slowly. </p><p id="p0031" num="0031"> Intravenously administered amphotericin B has also been associated with multiple organ damage in therapeutic doses. Nephrotoxicity (kidney damage) is a frequently reported side effect and can be severe and/or irreversible. </p><p id="p0032" num="0032"> Voriconazole (VFEND) is a triazole anti-fungal medication that is generally used to treat virulent or invasive mycosis. This type of mycosis is generally seen in patients who are immunocompromised, and includes invasive candidiasis, invasive aspergillosis, and certain emerging fungal infections. </p><p id="p0033" num="0033"> Voriconazole has become the new standard of care in the treatment of invasive aspergillosis, which may occur in immunocompromised patients, including allogeneic BMT, other hematologic cancers, and solid organ transplants. </p><p id="p0034" num="0034"> Voriconazole is better tolerated than amphotericin B, with fewer adverse effects and a longer duration of therapy . </p><p id="p0035" num="0035"> Voriconazole has proven to be as effective as a regimen of intravenous amphotericin B followed by oral fluconazole in patients with culture-proven candidemia. </p><p id="p0036" num="0036">Voriconazole cleared Candida yeast from the bloodstream as 
<!-- EPO <DP n="6"/>-->
quickly as amphotericin B (median 2 days) and showed a trend toward better survival. Voriconazole is also associated with fewer serious adverse events and cases of renal toxicity, but a higher incidence of visual disturbances was observed. </p><p id="p0037" num="0037"> Voriconazole has also been proven effective against a number of other serious fungal pathogens. These include infections by Fusarium spp. and Scedosporium </p><p id="p0038" num="0038">apiospermum (asexual form of Pseudallescheria boydii) . </p><p id="p0039" num="0039"> Although infrequently seen in the present clinical setting, these fungi are emerging as more common and deadly causes of fungal infection in immunocompromised patients, and the development of voriconazole has been an important advance in their treatment as they are generally resistant to other antifungal agents (including amphotericin B) . </p><p id="p0040" num="0040"> The most common side effects associated with voriconazole include transient visual disturbances, fever, rash, vomiting, nausea, diarrhea, headache, sepsis, </p><p id="p0041" num="0041">peripheral edema, abdominal pain, and respiratory disorder. Also cases of serious hepatic reactions during treatment with voriconazole have been reported. </p><p id="p0042" num="0042"> Itraconazole is a triazole anti-fungal agent that is prescribed to patients with mycosis. The drug may be given orally or intravenously. </p><p id="p0043" num="0043"> Itraconazole has a broader spectrum of activity than fluconazole (but not as broad as voriconazole or posaconazole ) . In particular, it is active against </p><p id="p0044" num="0044">Aspergillus, which fluconazole is not. It has been approved for the treatment of blastomycosis, histoplasmosis and onychomycosis. It is also prescribed for systemic infections such as aspergillosis, candidiasis and cryptococcosis where other antifungal drugs are inappropriate or ineffective. </p><p id="p0045" num="0045"> Itraconazole is a relatively well-tolerated drug (although not as well tolerated as fluconazole or 
<!-- EPO <DP n="7"/>-->
voriconazole) and the range of adverse effects it produces is similar to the other azole anti-fungals . </p><p id="p0046" num="0046"> Elevated alanine aminotransferase levels are found in 4% of people taking itraconazole forming a risk of developing congestive heart failure. Other reported adverse effects of itraconazole are nausea, vomiting, abdominal pain, fatigue, loss of appetite, yellow skin (jaundice), yellow eyes, itching, dark urine, and/or pale stool. </p><p id="p0047" num="0047"> Considering the above, there is a need in the art for anti-fungal agents being similarly effective as </p><p id="p0048" num="0048">amphotericin B, voriconazole and/or itraconazole with respect to anti-fungal activity but which are better tolerated, i.e. with less, reduced or less severe side effects . </p><p id="p0049" num="0049"> Further, considering the rapid development of resistance against known anti-fungal compounds, there is a continuing need in the art for further compounds with antifungal activity, and especially anti-fungal compounds effective against life threatening invasive or virulent fungal pathogens. </p><p id="p0050" num="0050"> Accordingly, it is an object of the present invention, amongst other objects, to provide anti-fungal compounds meeting the above needs in the art. </p><p id="p0051" num="0051"> According to the invention, this object, amongst other objects, according to a first aspect is met by appended claim 1. </p><p id="p0052" num="0052"> Specifically, this object, amongst other objects, according to a first aspect is met by oleyl phosphocholine for use in the treatment of mycosis in a vertebrate, preferably for use in the treatment of invasive or virulent mycosis in a vertebrate. 
<!-- EPO <DP n="8"/>-->
 Virulent mycosis as used herein indicates a primary fungal infection capable of extending, or spreading, the infected area of an organ or tissue infected. </p><p id="p0053" num="0053"> Invasive mycosis as used herein indicates a primary fungal infection capable of further infecting, or spreading to, other organs or tissues. </p><p id="p0054" num="0054"> In the present context, mycosis can be both virulent and invasive. </p><p id="p0055" num="0055"> According to a preferred embodiment of this aspect of the present invention, the present mycosis is selected from the group consisting of superficial mycosis, cutaneous mycosis, subcutaneous mycosis, and systemic mycosis and especially invasive or virulent subcutaneous mycosis or invasive or virulent systemic mycosis. </p><p id="p0056" num="0056"> According to another preferred embodiment of this aspect of the present invention, the present vertebrate is a human, preferably an immunocompromised patient. </p><p id="p0057" num="0057"> According to yet another preferred embodiment of this aspect of the present invention, the causative pathogen of the present mycosis is selected from the genus Candida, Aspergillus, Fusarium, Cryptococcus , Microsporum, </p><p id="p0058" num="0058">Sporothrix, Trichophyton and Scedosporium. </p><p id="p0059" num="0059"> According to an especially preferred embodiment of this aspect of the present invention, the present oleyl phosphocholine is used for the treatment of mycosis caused pathogens selected from the group consisting of Candida albicans, Candida parapsilosis, Candida glabrata, Candida krusei, Aspergillus fumigatus, Aspergillus niger, </p><p id="p0060" num="0060">Aspergillus terreus, Fusarium solani, Scedosporium </p><p id="p0061" num="0061">prolifacans, Cryptococcus neoformans, Microsporum canis, Sporothrix schenkii , Trichophyton rubrum, Trichophyton mentagrophytes, Aspergillus fumigatus, Fusarium oxysporum. 
<!-- EPO <DP n="9"/>-->
 According to another preferred embodiment of this aspect of the present invention, the present oleyl </p><p id="p0062" num="0062">phosphocholine is formulated for parenteral, oral or topical administration. Especially in case the present mycosis is subcutaneous mycosis oleyl phosphocholine is formulated for topical or oral administration and in case the present mycosis is systemic mycosis oleyl phosphocholine is </p><p id="p0063" num="0063">formulated intravenous, parenteral or oral administration. </p><p id="p0064" num="0064"> According to an especially preferred embodiment of the present invention, the present oleyl phosphocholine is used for the treatment of a mycosis selected from the group consisting of candidemia, aspergillosis and cryptococcosis. </p><p id="p0065" num="0065"> Considering the effective anti-fungal activity of oleyl phosphocholine, the present invention, according to another aspect, relates to methods for treatment of mycosis comprising administering to, or applying on a vertebrate suffering from mycosis, preferably invasive or virulent mycosis, a therapeutically effective dose of oleyl </p><p id="p0066" num="0066">phosphocholine . </p><p id="p0067" num="0067"> According to a preferred embodiment of this aspect, the present mycosis is caused by a yeast or fungus belonging to a genus selected from the group consisting of Candida, Aspergillus, Fusarium, Cryptococcus , Microsporum, Sporothrix, Trichophyton and Scedosporium such as pathogens selected from the group consisting of Candida albicans, Candida parapsilosis, Candida glabrata, Candida krusei, Aspergillus fumigatus, Aspergillus niger, Aspergillus terreus, Fusarium solani, Scedosporium prolifacans, </p><p id="p0068" num="0068">Cryptococcus neoformans, Microsporum canis, Sporothrix schenkii , Trichophyton rubrum, Trichophyton mentagrophytes, Aspergillus fumigatus, Fusarium oxysporum. </p><p id="p0069" num="0069"> According to yet another preferred embodiment of this aspect, the present invention relates to the present 
<!-- EPO <DP n="10"/>-->
use of oleyl phosphocholine formulated by parenteral, oral or topical administration. </p><p id="p0070" num="0070"> According to a particularly preferred embodiment of this aspect, oleyl phosphocholine is used for the </p><p id="p0071" num="0071">treatment of candidemia, aspergillosis and cryptococcosis. </p><p id="p0072" num="0072"> The present invention will be further detailed and illustrated in the examples below representing particularly preferred embodiments of the present invention. </p><p id="p0073" num="0073">Examples </p><p id="p0074" num="0074">Example 1 </p><p id="p0075" num="0075">The following ten strains were tested for assaying the anti-fungal activity of oleyl phosphocholine. One </p><p id="p0076" num="0076">Candida strain, i.e. 19114, was selected because of its resistance against voriconazole and itraconazole </p><p id="p0077" num="0077">Table 1: Strain tested for anti-fungal activity of oleyl phosphocholine </p><p id="p0078" num="0078">Strain </p><p id="p0079" num="0079"> Yeasts strain isolate remark </p><p id="p0080" num="0080"> Candida albicans 3731 ATCC 10231 </p><p id="p0081" num="0081"> Candida albicans 19114 clinical blood </p><p id="p0082" num="0082"> isolate resistant for voriconazole and itraconazole</p><p id="p0083" num="0083">Candida parapsilosis 3270 ATCC 22019 </p><p id="p0084" num="0084"> Candida glabrata 19371 clinical blood </p><p id="p0085" num="0085"> isolate </p><p id="p0086" num="0086"> Candida krusei 9560 ATCC 6258</p><p id="p0087" num="0087"> ilamentous fungi </p><p id="p0088" num="0088"> Aspergillus fumigatus 18963 NCPF 7367 </p><p id="p0089" num="0089"> Aspergillus niger 5788 ATCC 10864 </p><p id="p0090" num="0090"> Aspergillus terreus 13669 clinical isolate</p><p id="p0091" num="0091">Fusarium solani 18489 clinical isolate</p><p id="p0092" num="0092">Scedospori urn 22387 clinical blood prolifacans isolate 
<!-- EPO <DP n="11"/>-->
 The above strains were contacted with oleyl phosphocholine on microplates and the anti-fungal activity of oleyl phosphocholine was determined. In comparison, the same test was performed using amphotericin B (AMB) , </p><p id="p0093" num="0093">voriconazole (VRZ) and itraconazole (ITR) . </p><p id="p0094" num="0094">The test protocol used was in conformity with the standard CLSI method: </p><p id="p0095" num="0095">Clinical and Laboratory Standards Institute/National </p><p id="p0096" num="0096"> Committee for Clinical Laboratory Standards (2002) Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved Standard document M27-A2. Clinical and Laboratory Standards Institute/National Committee for </p><p id="p0097" num="0097">Clinical Laboratory Standards Institute, Wayne PA. </p><p id="p0098" num="0098">Clinical and Laboratory Standards Institute/National </p><p id="p0099" num="0099">Committee for Clinical Laboratory Standards. (2002) </p><p id="p0100" num="0100">Reference method for broth dilution antifungal </p><p id="p0101" num="0101">susceptibility testing of filamentous fungi. Approved </p><p id="p0102" num="0102"> Standard document M38-A. Clinical and Laboratory Standards Institute/National Committee for Clinical Laboratory </p><p id="p0103" num="0103">Standards Institute, Wayne </p><p id="p0104" num="0104"> The following concentrations of oleyl </p><p id="p0105" num="0105">phosphocholine (Dafra) , amphotericin B (AMB) , voriconazole (VRZ) and itraconazole (ITR) were tested: 10, 5, 2.5, 1.25, 0.625, 0.312, 0.15, 0.078, 0.039, 0.019, 0.009, and 0.004 μg/ml </p><p id="p0106" num="0106"> The results, after visual and spectrophometric reading after 48 hours of incubation, are presented as MIC50 and MIC 100, i.e. the minimum inhibitory concentration required inhibiting the growth of 50% or 100% of the </p><p id="p0107" num="0107">microorganisms, respectively. 
<!-- EPO <DP n="12"/>-->
 Table 2: Minimum inhibitory concentration required </p><p id="p0108" num="0108"> inhibiting the growth of 50% or 100% of the mi croorgani sms </p><p id="p0109" num="0109"><img id="imgf000012_0001" he="54" wi="167" file="imgf000012_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="yes"/></p><p id="p0110" num="0110"><img id="imgf000012_0002" he="59" wi="167" file="imgf000012_0002.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0111" num="0111">As can be seen in the above table, oleyl phosphocholine was capable of inhibiting the growth of yeast and fungi in a similar concentration range as the commonly used anti-fungal agents amphotericin B, voriconazole and itraconazole . </p><p id="p0112" num="0112"> Further, the results for the resistant Candida strain 19114 show that oleyl phosphocholine provides a suitable alternative for the known anti-fungal agents against which resistance has been developed. </p><p id="p0113" num="0113"> Of special interest is the anti-fungal activity of oleyl phosphocholine against Fusarium solani and </p><p id="p0114" num="0114">Scedosporium prolificans, two emerging pathogens, against at 
<!-- EPO <DP n="13"/>-->
least two of the known anti-fungal agents, i.e. voriconazole and itraconazole, are less effective. </p><p id="p0115" num="0115">Example 2 </p><p id="p0116" num="0116">The following strains were tested for assaying the anti-fungal activity of oleyl phosphocholine. </p><p id="p0117" num="0117">Table 3: Strains used for assaying the anti-fungal activity of oleyl phosphocholine . </p><p id="p0118" num="0118">Candida albicans </p><p id="p0119" num="0119"> Candida albicans B59630 (R) </p><p id="p0120" num="0120"> Candida albicans B63195 (S) </p><p id="p0121" num="0121"> Candida parapsilosis B66126 </p><p id="p0122" num="0122"> Cryptococcus neoformans </p><p id="p0123" num="0123"> Cryptococcus neoformans B66663 </p><p id="p0124" num="0124"> Microsporum canis </p><p id="p0125" num="0125"> Sporothrix schenkii </p><p id="p0126" num="0126"> Sporothrix schenkii B62482 </p><p id="p0127" num="0127"> Trichophyton rubrum </p><p id="p0128" num="0128"> Trichophyton rubrum B68183 </p><p id="p0129" num="0129"> Trichophyton mentagrophytes B70554 </p><p id="p0130" num="0130"> Aspergillus fumigatus </p><p id="p0131" num="0131">Aspergillus fumigatus B42928 </p><p id="p0132" num="0132"> Aspergillus fumigatus B19119 </p><p id="p0133" num="0133"> Fusarium solani IHEM22128 </p><p id="p0134" num="0134"> Fusarium oxysporum IHEM3014 </p><p id="p0135" num="0135">The above strains were contacted oleyl </p><p id="p0136" num="0136">phosphocholine on microplates and the anti-fungal activity of oleyl phosphocholine was determined. </p><p id="p0137" num="0137"> Anti-fungal activity was expressed as IC<sub>50</sub>, i.e. the concentration oleyl phosphocholine needed to kill 50% of the pathogens. The results are summarised in Table 4 below: 
<!-- EPO <DP n="14"/>-->
Table 4: In vitro efficacy of OIPC against yeasts and fungi expressed as IC<sub>50</sub> concentration . </p><p id="p0138" num="0138">OIPC IC<sub>50</sub> </p><p id="p0139" num="0139"> Yeasts/Fungi (μΜ) </p><p id="p0140" num="0140"> Candida albicans 7.89 </p><p id="p0141" num="0141"> Candida albicans B59630 (R) 8.00 </p><p id="p0142" num="0142"> Candida albicans B63195 (S) 7.77 </p><p id="p0143" num="0143"> Candida parapsilosis B66126 8.00 </p><p id="p0144" num="0144"> Cryptococcus neoformans 4.50 </p><p id="p0145" num="0145"> Cryptococcus neoformans B66663 0.50 </p><p id="p0146" num="0146"> Microsporum canis 1.66 </p><p id="p0147" num="0147"> Sporothrix schenkii 8.16 </p><p id="p0148" num="0148"> Sporothrix schenkii B62482 1.97 </p><p id="p0149" num="0149"> Trichophyton rubrum 5.87 </p><p id="p0150" num="0150"> Trichophyton rubrum B68183 2.00 </p><p id="p0151" num="0151"> Trichophyton mentagrophytes B70554 2.00 </p><p id="p0152" num="0152"> Aspergillus fumigatus 18.76 </p><p id="p0153" num="0153"> Aspergillus fumigatus B42928 8.00 </p><p id="p0154" num="0154"> Aspergillus fumigatus B19119 1.87 </p><p id="p0155" num="0155"> Fusarium solani IHEM22128 2.31 </p><p id="p0156" num="0156"> Fusarium oxysporum IHEM3014 2.55 
</p></description><claims mxw-id="PCLM44998389" ref-ucid="WO-2012119870-A1" lang="EN" load-source="patent-office"><claim-statement><!-- EPO <DP n="15"/>-->CLAIMS </claim-statement><claim id="clm-0001" num="1"><claim-text>1. Oleyl phosphocholine for use in the treatment mycosis in a vertebrate, preferably for use in the treatment of invasive or virulent mycosis in a vertebrate. </claim-text></claim><claim id="clm-0002" num="2"><claim-text>2. Use according to claim 1, wherein said mycosis is selected from the group consisting of superficial </claim-text><claim-text>mycosis, cutaneous mycosis, subcutaneous mycosis, and systemic mycosis. </claim-text></claim><claim id="clm-0003" num="3"><claim-text>3. Use according to claim 1 or claim 2, wherein said mycosis is invasive or virulent subcutaneous mycosis or invasive or virulent systemic mycosis. </claim-text></claim><claim id="clm-0004" num="4"><claim-text>4. Use according to any of the claims 1 to 3, wherein said vertebrate is a human, preferably an </claim-text><claim-text>immunocompromised patient. </claim-text></claim><claim id="clm-0005" num="5"><claim-text>5. Use according to any of the claims 1 to 4, wherein the causative pathogen of said mycosis is selected from the genus Candida, Aspergillus, Fusarium, Cryptococcus, Microsporum, Sporothrix, Trichophyton and Scedosporium. </claim-text></claim><claim id="clm-0006" num="6"><claim-text>6. Use according to any of the claims 1 to 5, wherein the causative pathogen of said mycosis is selected from the group consisting of Candida albicans, Candida parapsilosis, Candida glabrata, Candida krusei, Aspergillus fumigatus, Aspergillus niger, Aspergillus terreus, Fusarium solani, Scedosporium prolifacans, Cryptococcus neoformans, Microsporum canis, Sporothrix schenkii , Trichophyton rubrum, Trichophyton mentagrophytes, Aspergillus fumigatus, Fusarium oxysporum. <!-- EPO <DP n="16"/>--> </claim-text></claim><claim id="clm-0007" num="7"><claim-text>7. Use according to any of the claims 1 to 6, wherein said oleyl phosphocholine is formulated for </claim-text><claim-text>parenteral, oral or topical administration. </claim-text></claim><claim id="clm-0008" num="8"><claim-text>8. Use according to any of the claims 1 to 7, wherein said mycosis is systemic mycosis and said </claim-text><claim-text>formulation is for intravenous or oral administration. </claim-text></claim><claim id="clm-0009" num="9"><claim-text>9. Use according to any of the claims 1 to 7, wherein said mycosis is subcutaneous mycosis and said formulation is for topical or oral administration. </claim-text></claim><claim id="clm-0010" num="10"><claim-text>10. Use according to any of the claims 1 to 9, wherein said mycosis is selected from the group consisting of candidemia, aspergillosis and cryptococcosis. </claim-text></claim><claim id="clm-0011" num="11"><claim-text>11. Method for treatment of mycosis comprising administering to, or applying on a vertebrate suffering from mycosis, preferably invasive or virulent mycosis, a </claim-text><claim-text>therapeutically effective dose of oleyl phosphocholine </claim-text></claim><claim id="clm-0012" num="12"><claim-text>12. Method according to claim 11, wherein said mycosis is selected from the group consisting of superficial mycosis, cutaneous mycosis, subcutaneous mycosis, and systemic mycosis. </claim-text></claim><claim id="clm-0013" num="13"><claim-text>13. Method according to claim 11 or claim 12, wherein said mycosis is invasive or virulent subcutaneous mycosis or invasive or virulent systemic mycosis. <!-- EPO <DP n="17"/>--> </claim-text></claim><claim id="clm-0014" num="14"><claim-text>14. Method according to any of the claims 11 to</claim-text><claim-text>13, wherein said vertebrate is a human, preferably an immunocompromised patient. </claim-text></claim><claim id="clm-0015" num="15"><claim-text>15. Method according to any of the claims 11 to</claim-text><claim-text>14, wherein the causative pathogen of said mycosis is selected from the genus Candida, Aspergillus, Fusarium, Cryptococcus , Microsporum, Sporothrix, Trichophyton and Scedospori urn . </claim-text></claim><claim id="clm-0016" num="16"><claim-text>16. Method according to any of the claims 11 to 14, wherein the causative pathogen of said mycosis is selected from the group consisting of Candida albicans, Candida parapsilosis, Candida glabrata, Candida krusei, Aspergillus fumigatus, Aspergillus niger, Aspergillus terreus, Fusarium solani, Scedosporium prolifacans, </claim-text><claim-text>Cryptococcus neoformans, Microsporum canis, Sporothrix schenkii , Trichophyton rubrum, Trichophyton mentagrophytes, Aspergillus fumigatus, Fusarium oxysporum. </claim-text></claim><claim id="clm-0017" num="17"><claim-text>17. Method according to any of the claims 11 to 16, wherein said oleyl phosphocholine is formulated for parenteral, oral or topical administration. </claim-text></claim><claim id="clm-0018" num="18"><claim-text>18. Method according to any of the claims 11 to</claim-text><claim-text>16, wherein said mycosis is systemic mycosis and said formulation is for intravenous or oral administration. </claim-text></claim><claim id="clm-0019" num="19"><claim-text>19. Method according to any of the claims 11 16, wherein said mycosis is subcutaneous mycosis and s formulation is for topical or oral administration. <!-- EPO <DP n="18"/>--> </claim-text></claim><claim id="clm-0020" num="20"><claim-text>20. Method according to any of the claims 11 to 19, wherein said mycosis is selected from the group consisting of candidemia, aspergillosis and cryptococcosis </claim-text></claim></claims><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
